Treatment of cutaneous T-cell lymphomas with purine analogues (fludarabine and 2-chlorodeoxyadenosine)

Journal of B.U.ON.

Volumn 8, Issue 3, 2003, Pages 247-251

  Mazur, Grzegorz ^a   Maj, J ^a   Wrobel, T ^a   Hryncewicz Gwozdz, A ^a   Niezgoda, E ^a   Kuliczkowski, K ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

2 Chlorodeoxyadenosine; Cutaneous lymphoma; Fludarabine; Purine analogues

Indexed keywords

ALPHA INTERFERON; AMSACRINE; AZATHIOPRINE; CLADRIBINE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUDARABINE PHOSPHATE; HYDROCORTISONE; INTERFERON; METHOTREXATE; MITOXANTRONE; PREDNISONE; PSORALEN; PURINE DERIVATIVE; RETINOIC ACID; VINBLASTINE; VINCRISTINE SULFATE;

ADULT; AGED; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DISEASE SEVERITY; DNA DAMAGE; DRUG EFFICACY; DRUG TOXICITY; FEMALE; HERPES ZOSTER; HOSPITAL PATIENT; HUMAN; IMMUNOPATHOLOGY; INFECTION; LEUKOPENIA; MALE; MONOTHERAPY; PNEUMONIA; SEPSIS; SKIN DEFECT; THROMBOCYTOPENIA; ULTRAVIOLET A RADIATION;

EID: 0344013489     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Burg G, Drummer R, Ken H. Classification of cutaneous lymphomas. Derm Clin 1994; 12: 213-217.
2. Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002; 46: 525-355.
3. Wolff JM, Zitelli JA, Rabin BS, Smiles KA, Abel E. Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol 1985; 13: 604-612.
4. Duvic M, Martin A, Kim Y, Olsen E, Wood G, Yocum R. Oral bexaroten is safe and effective in phase II-III clinical trial in refractory or persistent early stage CTCL. Blood 1999; 94: 659a.
5. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999; 86: 1368-1376.
6. Bunn PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Ann Intern Med 1994; 121: 592-602.
7. Zinzani PL, Tosi P, Visani G et al. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994; 47: 301-306.
8. Saven A, Piro LD. 2-Chlorodeoxyadenosine: A potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Hematol Cell Ther 1996; 38 (2S): 93-101.
9. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1003-1037.
10. Bordanaro R, Ferrau F, Giuffrida D et al. Fludarabine phosphate as an active and well tolerated salvage therapy in an elderly heavily pretreated Hodgkin's disease patient: A case report. Tumori 1999; 85: 288-289.
11. Kong LR, Samuelson E, Rosen ST et al. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. Leuk Lymphoma 1997; 26: 89-97.
12. Kuzel TM, Hurria A, Samuelson E et al. Phase II trial of 2-Chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996; 87: 906-911.
13. Nikko AP, Rutherford CJ, Pandya AG. Successful treatment of Sezary syndrome with lymphomatous transformation to large cell lymphoma with fludarabine phosphate. Arch Dermatol 1996; 132: 978-979.
14. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxy-adenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 80: 587-592.
15. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group study. J Natl Cancer Inst 1990; 82: 1353-1355.
16. Rook AH, Wood GS, Yoo EK et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902-908.
17. Knox S, Hoppe RT, Maloney D. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996; 87: 893-899.
18. Bouwhuis SA, El-Azhary RA, McEvoy MT et al. Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. Int J Dermatol 2002; 41: 352-356.
19. Sezer O, Schmid P, Hallek M et al. Eosinophilia during fludarabine treatment of chronic lymphocytic leukaemia. Ann Hematol 1999; 78: 475-477.